Dual physiologically based pharmacokinetic model of liposomal and nonliposomal amphotericin B disposition

Pharmaceutical Research

Volumn 31, Issue 1, 2014, Pages 35-45

  Kagan, Leonid ^a   Gershkovich, Pavel ^b   Wasan, Kishor M ^c   Mager, Donald E ^d  

^a RUTGERS UNIVERSITY   (United States)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY AT BUFFALO   (United States)

Author keywords

amphotericin B; interspecies scaling; physiologically based pharmacokinetic model; tissue distribution

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG TISSUE LEVEL; LIVER; MAXIMUM PLASMA CONCENTRATION; MICHAELIS MENTEN KINETICS; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT; RETICULOENDOTHELIAL SYSTEM; SPLEEN; TISSUE DISTRIBUTION;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; BODY WEIGHT; HUMANS; LIPOSOMES; LIVER; MICE; RATS; SPLEEN; TISSUE DISTRIBUTION;

EID: 84891631526     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1127-z     Document Type: Article

References (45)

1. Thornton SJ, Wasan KM. The reformulation of amphotericin B for oral administration to treat systemic fungal infections and visceral leishmaniasis. Expert Opin Drug Deliv. 2009;6(3):271-84.
2. Thornton SJ, Wasan KM, Piecuch A, Lynd LL, Wasan EK. Barriers to treatment for visceral leishmaniasis in hyperendemic areas: India, Bangladesh, Nepal, Brazil and Sudan. Drug Dev Ind Pharm. 2010;36(11):1312-9.
3. Adler-Moore J, Proffitt RT. Am Bisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother. 2002;49 Suppl 1:21-30. (Pubitemid 34162653)
4. Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson RN, et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis Off Publ Infect Dis Soc Am. 2006;43(7):917-24. (Pubitemid 44435523)
5. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413-20.
6. Gershkovich P, Wasan EK, Lin M, Sivak O, Leon CG, Clement JG, et al. Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation. J Antimicrob Chemother. 2009;64(1):101-8.
7. Davidson EM, Barenholz Y, Cohen R, Haroutiunian S, Kagan L, Ginosar Y. High-dose bupivacaine remotely loaded into multivesicular liposomes demonstrates slow drug release without systemic toxic plasma concentrations after subcutaneous administration in humans. Anesth Analg. 2010;110(4):1018-23.
8. Adler-Moore JP, Proffitt RT. Amphotericin B lipid preparations: what are the differences? Clinical Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2008;14 Suppl 4:25-36. (Pubitemid 351593914)
9. Landsiedel R, Fabian E, Ma-Hock L, Wohlleben W, Wiench K, Oesch F, et al. Toxico-/biokinetics of nanomaterials. Archives of toxicology. 2012.
10. Li SD, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm. 2008;5(4):496-504.
11. Martinez MN. Factors influencing the use and interpretation of animal models in the development of parenteral drug delivery systems. AAPS J. 2011;13(4):632-49.
12. Harashima H, Komatsu S, Kojima S, Yanagi C, Morioka Y, Naito M, et al. Species difference in the disposition of liposomes among mice, rats, and rabbits: allometric relationship and species dependent hepatic uptake mechanism. Pharm Res. 1996;13(7):1049-54. (Pubitemid 26259005)
13. Gershkovich P, Wasan EK, Sivak O, Li R, Zhu X, Werbovetz KA, et al. Visceral leishmaniasis affects liver and spleen concentrations of amphotericin B following administration to mice. J Antimicrob Chemother. 2009.
14. Benson JM, Nahata MC. Pharmacokinetics of amphotericin B in children. Antimicrob Agents Chemother. 1989;33(11):1989-93. (Pubitemid 19266266)
15. Graybill JR. Is there a correlation between serum antifungal drug concentration and clinical outcome? J Infect. 1994;28 Suppl 1:17-24. (Pubitemid 24158709)
16. Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol. 2011;51:45-73.
17. Kagan L, Gershkovich P, Wasan KM, Mager DE. Physiologically based pharmacokinetic model of amphotericin B disposition in rats following administration of deoxycholate formulation (Fungizone®): pooled analysis of published data. AAPS J. 2011;13(2):255-64.
18. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health. 1997;13(4):407-84. (Pubitemid 27314117)
19. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993;10(7):1093-5. (Pubitemid 23211439)
20. Gerlowski LE, Jain RK. Physiologically based pharmacokinetic modeling: principles and applications. J Pharm Sci. 1983;72(10):1103-27. (Pubitemid 13013622)
21. Tsuji A, Yoshikawa T, Nishide K, Minami H, Kimura M, Nakashima E, et al. Physiologically based pharmacokinetic model for beta-lactam antibiotics I: tissue distribution and elimination in rats. J Pharm Sci. 1983;72(11):1239-52. (Pubitemid 14229729)
22. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, Inc.; 1982.
23. Robbie G, Chiou WL. Elucidation of human amphotericin B pharmacokinetics: identification of a new potential factor affecting interspecies pharmacokinetic scaling. Pharm Res. 1998;15(10):1630-6. (Pubitemid 28465752)
24. Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother. 2002;46(3):834-40. (Pubitemid 34157671)
25. Wang LH, Fielding RM, Smith PC, Guo LS. Comparative tissue distribution and elimination of amphotericin B colloidal dispersion (Amphocil) and Fungizone after repeated dosing in rats. Pharm Res. 1995;12(2):275-83.
26. Chow HH, Wu Y, Mayersohn M. Pharmacokinetics of amphotericin B in rats as a function of dose following constant-rate intravenous infusion. Biopharm Drug Dispos. 1995;16(6):461-73.
27. Matsui S, Imai S, Yabuki M, Komuro S. Pharmacokinetics characterization of liposomal amphotericin B: investigation of clearance process and drug interaction potential. Arzneimittelforschung. 2009;59(9):461-70.
28. Kawai R, Lemaire M, Steimer JL, Bruelisauer A, Niederberger W, Rowland M. Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125. J Pharmacokinet Biopharm. 1994;22(5):327-65.
29. Harashima H, Kume Y, Yamane C, Kiwada H. Non-michaelis-menten type hepatic-uptake of liposomes in the rat. J Pharm Pharmacol. 1992;44(9):707-12.
30. Kume Y, Maeda F, Harashima H, Kiwada H. Saturable, non-Michaelis-Menten uptake of liposomes by the reticuloendothelial system. J Pharm Pharmacol. 1991;43(3):162-6.
31. Tollemar J, Ringden O, Tyden G. Liposomal amphotericin-B (Ambisome) treatment in solid organ and bone-marrow transplant recipients - efficacy and safety evaluation. Clin Transplant. 1990;4(3):167-75. (Pubitemid 20173936)
32. Ringden O, Meunier F, Tollemar J, Ricci P, Tura S, Kuse E, et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother. 1991;28(Suppl B):73-82.
33. Hong Y, Ramzan I, McLachlan AJ. Disposition of amphotericin B in the isolated perfused rat liver. J Pharm Pharmacol. 2004;56(1):35-41. (Pubitemid 38195326)
34. Angra PK, Siddig A, Nettey H, Desai N, Oettinger C, D'Souza MJ. Pharmacokinetic and biodistribution studies of amphotericin B microspheres. J Microencapsul. 2009;26(7):627-34.
35. Fielding RM, Smith PC, Wang LH, Porter J, Guo LS. Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob Agents Chemother. 1991;35(6):1208-13.
36. Chow DD, Essien HE, Padki MM, Hwang KJ. Targeting small unilamellar liposomes to hepatic parenchymal cells by dose effect. J Pharmacol Exp Ther. 1989;248(2):506-13. (Pubitemid 19090216)
37. Li M, Al-Jamal KT, Kostarelos K, Reineke J. Physiologically based pharmacokinetic modeling of nanoparticles. ACS nano. 2010;4(11):6303-17.
38. Harashima H, Iida S, Urakami Y, Tsuchihashi M, Kiwada H. Optimization of antitumor effect of liposomally encapsulated doxorubicin based on simulations by pharmacokinetic/pharmacodynamic modeling. J control Rel Off J Control Rel Soc. 1999;61(1-2):93-106. (Pubitemid 29406083)
39. Liu D, Hu Q, Song YK. Liposome clearance from blood: different animal species have different mechanisms. Biochim Biophys Acta. 1995;1240(2):277-84. (Pubitemid 26004752)
40. Caron WP, Clewell H, Dedrick R, Ramanathan RK, Davis WL, Yu N, et al. Allometric scaling of pegylated liposomal anticancer drugs. J Pharmacokinet Pharmacodyn. 2011;38(5):653-69.
41. van Etten EW, Otte-Lambillion M, van Vianen W, ten Kate MT, Bakker-Woudenberg AJ. Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans. J Antimicrob Chemother. 1995;35(4):509-19.
42. Sivak O, Gershkovich P, Lin M, Wasan EK, Zhao J, Owen D, et al. Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model. Lipids Health Dis. 2011;10:135.
43. Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother. 2002;46(3):828-33. (Pubitemid 34157670)
44. Proffitt RT, Satorius A, Chiang SM, Sullivan L, Adler-Moore JP. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J Antimicrob Chemother. 1991;28(Suppl B):49-61.
45. Smith PJ, Olson JA, Constable D, Schwartz J, Proffitt RT, Adler-Moore JP. Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B. J Antimicrob Chemother. 2007;59(5):941-51. (Pubitemid 47073366)